Zacks Investment Research Downgrades International Stem Cell (OTCMKTS:ISCO) to Sell

Share on StockTwits

International Stem Cell (OTCMKTS:ISCO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. “

ISCO stock traded down $0.02 during midday trading on Tuesday, reaching $1.05. 419 shares of the company were exchanged, compared to its average volume of 6,037. The company has a current ratio of 0.79, a quick ratio of 0.46 and a debt-to-equity ratio of 0.32. International Stem Cell has a 1-year low of $0.68 and a 1-year high of $1.90. The company’s 50-day moving average price is $0.89. The company has a market capitalization of $7.91 million, a P/E ratio of -3.18 and a beta of 0.51.

International Stem Cell (OTCMKTS:ISCO) last posted its quarterly earnings data on Friday, May 17th. The biotechnology company reported ($0.12) earnings per share for the quarter. The firm had revenue of $2.22 million during the quarter. International Stem Cell had a negative net margin of 12.51% and a negative return on equity of 52.75%. As a group, sell-side analysts predict that International Stem Cell will post -0.39 EPS for the current year.

International Stem Cell Company Profile

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes.

Recommended Story: What is meant by holder of record?

Get a free copy of the Zacks research report on International Stem Cell (ISCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Downgrades International Stem Cell  to Sell
Zacks Investment Research Downgrades International Stem Cell to Sell
Morgan Stanley Reiterates $68.00 Price Target for XPO Logistics
Morgan Stanley Reiterates $68.00 Price Target for XPO Logistics
Rwe Ag Sp  Stock Rating Upgraded by Zacks Investment Research
Rwe Ag Sp Stock Rating Upgraded by Zacks Investment Research
Zacks: Analysts Anticipate ON Semiconductor Corp  Will Announce Quarterly Sales of $1.38 Billion
Zacks: Analysts Anticipate ON Semiconductor Corp Will Announce Quarterly Sales of $1.38 Billion
JPMorgan Chase & Co. Initiates Coverage on Playtech
JPMorgan Chase & Co. Initiates Coverage on Playtech
Aimmune Therapeutics  Rating Lowered to Hold at Zacks Investment Research
Aimmune Therapeutics Rating Lowered to Hold at Zacks Investment Research


 
© 2006-2019 Zolmax.